Partner Dennis Gucciardo was quoted in a MedTech Dive article about the outlook for the US Food and Drug Administration (FDA) under the Biden administration. Dennis noted that companies can expect an increase in “for cause” FDA inspections. "Under the Trump administration, we didn't really see that kind of activity unless there was a public health threat," he said.